Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC vCP1452 and AIDSVAX B/B for HIV Prevention
NCT00007332Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ALVAC-HIV vCP1452, AIDSVAX B/B in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Status: completed.
02
Drugs
ALVAC-HIV vCP1452AIDSVAX B/B
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00007332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00007332.